Company intelligence / Profile preview

Swecure

Gothenburg (Gothenburg region inferred from association with The Sahlgrenska Academy)[1], Swedensecure.login.gov ↗

Ownership: Private
Development stage: Commercial

Overview

Swecure develops novel therapies targeting immunoregulatory disorders by modulating the gut microbiome, with a focus on allergy prevention and treatment as well as inflammatory bowel disease. The company leverages over two decades of academic research in bacteriology and immunology from The Sahlgrenska Academy. No published late-stage clinical results are available; programs appear to be in pre-clinical or early clinical stages[1][2].

Therapeutic areas: GastroenterologyImmunology
Modalities: Microbial therapy (based on gut microbiome research)Live biotherapeutic product therapy
Industry: Biotech

Drug pipeline

1 asset

SWE-01

Preclinical

Partnerships

Not publicly disclosed.

Beyond the preview

Go deeper on Swecure.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Swecure.

Explore the full profile